KRYS vs NDAQ · P/E 46, rev $235.6M vs P/E 41, rev $2.53B
Krystal Biotech Inc (KRYS) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
Krystal Biotech Inc (KRYS) is a biotechnology company listed on NASDAQ.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
Latest reported KRYS revenue for 2026-06-30 was $235.6M. Net income was $110.7M. KRYS currently screens at market cap $10.17B and trailing P/E 46.1.
Latest reported NDAQ revenue for 2026-06-30 was $2.53B. Net income was $507.0M. Revenue was up 18.5% from 2026-03-31 to 2026-06-30. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
KRYS currently screens at market cap $10.17B and trailing P/E 46.1. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the KRYS and NDAQ stock pages for the full models.
Not investment advice.